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Bacterial pneumonia is a major cause of acute lung injury and acute respiratory distress syndrome, 
characterized by alveolar barrier disruption. NLRP3 is best known for its ability to form inflammasomes 
and to regulate IL-1β and IL-18 production in myeloid cells. Here we show that NLRP3 protects the 
integrity of the alveolar barrier in a mouse model of Streptococcus pneumoniae-induced pneumonia, 
and ex vivo upon treatment of isolated perfused and ventilated lungs with the purified bacterial toxin, 
pneumolysin. We reveal that the preserving effect of NLRP3 on the lung barrier is independent of 
inflammasomes, IL-1β and IL-18. NLRP3 improves the integrity of alveolar epithelial cell monolayers 
by enhancing cellular adherence. Collectively, our study uncovers a novel function of NLRP3 by 
demonstrating that it protects epithelial barrier function independently of inflammasomes.
Bacterial and viral pneumonias are the most common causes of acute lung injury (ALI) and acute respiratory 
distress syndrome (ARDS)1,2. Central to both conditions is an increased leakage of the alveolar epithelial and 
endothelial barriers, and an uncontrolled activation of inflammation as well as coagulation pathways1–3. The 
impairment of the alveolar barrier function can be caused by the inflammatory host response leading to recruit-
ment of neutrophils to the alveoli and by microbial factors such as bacterial toxins. Whereas the molecular mech-
anisms of lung endothelial stabilization are increasingly well understood, less is known about the pathways that 
protect the epithelial barrier in the lung1.
Streptococcus pneumoniae is the major cause of community-acquired pneumonia, which can deteriorate to 
ALI and ARDS4,5. One of the most important pneumococcal virulence factors is the toxin pneumolysin (PLY)6,7. 
PLY is a member of the cholesterol-dependent cytolysins expressed by various Gram-positive bacteria. PLY of 
most pneumococci binds to cholesterol-containing membranes, forms large pores upon oligomerization, and 
thereby causes cell lysis. At sublytic concentrations, PLY has been additionally described to activate the comple-
ment system and to stimulate cytokine production in monocytes and macrophages6,7. Previous studies identified 
PLY as critical mediator of lung barrier disruption during pneumococcal pneumonia8–11. This detrimental effect 
is likely dependent on direct effects of PLY on the alveolar epithelial and/or endothelial cells, and may result in 
alveolar flooding and haemorrhage during the early stage of pneumococcal pneumonia11.
The NOD-like receptor molecule NLRP3 is best known for its ability to form inflammasomes. Canonical 
inflammasomes are macromolecular complexes consisting of a receptor molecule belonging to the NOD-like 
receptor (such as NLRP3) or the PYHIN protein families (e.g. AIM2), the adapter molecule ASC and 
caspase-112,13. Inflammasomes regulate the production of IL-1β and IL-18 by a caspase-1-dependent processing of 
the cytokine pro-forms into mature cytokines, and induce a caspase-1-dependent inflammatory cell death called 
pyroptosis12. The NLRP3 inflammasome is activated in response to many pathogen-derived, environmental, and 
endogenous host molecules14. We and others recently showed that the NLRP3 inflammasome senses PLY activity 
upon pneumococcal infection, and mediates IL-1β and IL-18 production by macrophages and dendritic cells15–19. 
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Unlike NLRP3 in myeloid cells, little is known about the function of this molecule in the epithelium, although 
several reports indicated that NLRP3 is expressed in different types of epithelial cells20–22.
In the present study, we employ different in vivo, ex vivo, and in vitro models to examine the effect of NLRP3 
on the lung barrier integrity during pneumococcal infection and response to PLY. Surprisingly, we found that 
NLRP3 protects the alveolar wall by preventing detachment of epithelial cells. These lung barrier stabilizing effect 
of NLRP3 was independent of inflammasomes, IL-1β and IL-18. Our study thus uncovers a hitherto unknown 
function of NLRP3, which might have implications for the development of barrier stabilizing therapeutic 
strategies.
Results
NLRP3 protects the lung barrier during pneumococcal infection and treatment with PLY. In 
order to examine the effect of NLRP3 on lung barrier function during pneumonia, mice were intranasally infected 
for 24 h with a S. pneumoniae serotype 3 strain (PN36). Human serum albumin (HSA) was intravenously admin-
istered to measure the leakage of HSA from the circulation into the alveolar space at 24 hrs post infection (p.i.). 
In confirmation of previous studies18,23, we found that pneumococcal pneumonia increases alveolar-capillary 
barrier leakage as indicated by enhanced levels of HSA in bronchoalveolar lavage fluid (BALF) compared to 
uninfected mice (Fig. 1a). Next we compared WT and NLRP3-deficient animals, and found an increased S. 
pneumoniae-induced barrier dysfunction in Nlrp3− /− compared to WT animals at 24 h post infection (Fig. 1a). 
Neutrophil recruitment into the alveolar space, bacterial loads in the lung, as well as IL-1β and IL-18 production 
were not significantly affected by NLRP3 at this early time point (Fig. 1b–e). This unaltered cytokine production 
Figure 1. NLRP3 protects the alveolar barrier during pneumococcal pneumonia and PLY treatment. 
(a–e) 8–10 week old female mice were intranasally infected with 5 × 106 S. pneumoniae PN36 for 24 h. (a) Lung 
permeability was quantified by measuring the HSA BALF/serum ratio after i.v. injection of HSA. Bacterial loads 
in BALF (b), neutrophil infiltration (c), as well as IL-1β (d) and IL-18 production (e) were measured 24 h post 
infection. (f,g) 8–10 week old female mice were intranasally infected with 5 × 106 S. pneumoniae D39 for 24 h 
and lung permeability was quantified by measuring the HSA BALF/serum ratio in BALF after i.v. injection of 
HSA (f). Bacterial loads 24 h p.i were measured in BALF (g). (h) Isolated perfused and ventilated lungs from 
WT and Nlrp3− /− mice were intratracheally treated with PBS or PLY (0,2 μ g/ml), and lung permeability was 
determined 30 min after stimulation by measuring leakage of HSA from the perfusion system to the broncho-
alveolar space. Values are given as mean ± SEM; n = 7–11. * p < 0.05, * * p < 0.01, n.s. = not significant.
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in Nlrp3− /− mice most likely reflects the involvement of additional inflammasomes (such as the AIM2 inflam-
masome) in controlling cytokine production15,24. Nlrp3− /− animals also showed enhanced lung barrier leakage 
(but not increased bacterial loads or altered cytokine production) after infection with a different pneumococcal 
strain (serotype 2 strain D39) in comparison to WT mice (Fig. 1f,g, and supplementary Fig. S1).
Given that PLY is critical for lung barrier dysfunction during pneumococcal pneumonia8–11, we next exam-
ined the effect of NLRP3 on the PLY-induced lung barrier dysfunction. Therefore, we used an ex vivo model 
which allowed for a more defined examination of NLRP3-mediated effects on barrier integrity, without the 
confounding influence of different host defence capacities in WT and Nlrp3− /− animals during pneumonia4. 
Isolated perfused and ventilated mouse lungs (IPMLs) were intravenously injected with HSA and challenged with 
PLY for 30 min to measure barrier integrity in analogy to the in vivo model (supplementary Fig. S2). Similarly to 
our in vivo results, we found that lungs of Nlrp3− /− animals exhibited increased HSA leakage compared to WT 
organs (Fig. 1g). These data demonstrate alveolar barrier stabilizing effects of NLRP3 during bacterial pneumonia 
and PLY treatment.
NLRP3 enhances lung epithelial barrier function. The alveolar barrier is a delicate structure measuring 
less than 1 μ m in diameter and is composed of an inner endothelial and an outer epithelial cell layer, separated 
by the basal membrane. The integrity of the alveolar barrier is absolutely vital to maintain sufficient gas exchange 
and thus organ function. In order to shed light on the NLRP3-mediated barrier protective effects, we examined 
the resistance, as a marker of “tightness” of monolayers of epithelial and endothelial cells. Primary murine lung 
endothelial cells (MLECs) and alveolar epithelial cells (AECs) from WT and Nlrp3− /− animals were isolated 
(Fig. 2a,b) and grown on microelectrodes connected to an electrical cell-substrate impedance system (ECIS)10,23. 
Figure 2. NLRP3 enhances resistance of alveolar epithelial cell monolayers against PLY-dependent 
interruption. MLECs and AECs from WT (black line) and Nlrp3− /− (red line) mice were isolated and their 
purity was determined by flow cytometry (a,b). MLECs (c) and AECs (d), as well as AECs co-cultured with 
alveolar macrophages (AMΦ ) (e) were grown on ECIS electrodes. The cell monolayers were treated with 1 μ g/mL 
PLY and resistance was measured continuously for 2 h by ECIS. Values represent a mean of at least 4 independent 
experiments performed in duplicates and are given as mean ± SEM. Statistical significance of the resistance drop was 
measured 30 min after PLY stimulation (indicated by grey dotted line). * p < 0.05, * * p < 0.01, n.s. = not significant.
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Upon exposure to PLY, transcellular electrical resistance values from each microelectrode was continuously mon-
itored and normalized to baseline resistance. As expected, PLY treatment led to a drop of the resistance indicat-
ing endothelial and epithelial barrier dysfunction (Fig. 2c,d). Notably, NLRP3-deficient AECs showed enhanced 
barrier dysfunction in response to PLY treatment, whereas lack of NLRP3 did not influence the MLEC barrier 
function. The purity of isolated AECs was greater than 95%, rendering responsibility of contaminating mac-
rophages for the protective effect of NLRP3 unlikely. Moreover, addition of WT alveolar macrophages (AMΦ ) 
to Nlrp3− /− AEC monolayers did not affect barrier resistance (Fig. 2e). Collectively, these data suggest that 
intraepithelial NLRP3 protects the lung epithelial barrier function.
The protective effect of NLRP3 on the alveolar barrier is independent of inflammasomes, IL-1β 
and IL-18. The NLRP3 is best known for its role in forming inflammasomes and in controlling IL-1β as well 
as IL-18 production12,14, and IL-18 has been implicated in protecting the intestinal barrier25,26. We therefore tested 
if (additional) inflammasome components, IL-18 or IL-1β are involved in lung barrier protection by NLRP3. 
Surprisingly, we found that PLY treatment led to a comparable barrier dysfunction in lungs from WT, Asc− /− , 
Il1b− /− and Il18− /− mice ex vivo (Fig. 3a–c). Similarly, deficiency of Caspase-1/11, IL-1 or IL-18 had no effect 
on the resistance of AEC monolayers as measured by ECIS (Fig. 3d–f). In order to exclude the possibility that 
the NLRP3-specific effects on the lung barrier are caused by a secondary mutation in the mouse strain used, we 
examined lungs of an independently generated NLRP3-deficient mouse strain (obtained from The Jackson lab-
oratory) in our ex vivo IPML model. Similarly to our results shown in Fig. 1g, we found the PLY-induced barrier 
dysfunction was enhanced in Jax® Nlrp3− /− mice (Nlrp3− /− J) compared to WT controls (Fig. 3h). Collectively, 
these data demonstrate that NLRP3 protects the lung epithelial barrier independently of inflammasomes, IL-1β 
and IL-18.
NLRP3 prevents detachment of lung epithelial cells from fibronectin surfaces. Using a math-
ematical tool of the ECIS software, the resistance of cell monolayers measured by ECIS can be divided into two 
parameters. α is the electrical current flow under the cells, representing the adhesion of the cell layer on the 
surface. Rb is the current flow between cells and represents the permeability of the cell barrier27–30. To deter-
mine the effect of NLRP3 on the adhesion and permeability of alveolar epithelial cell layers, we treated WT and 
Nlrp3− /− cells with PLY and plotted the 1/α and 1/Rb over time. The epithelial cell adhesion was significantly 
decreased in PLY-treated Nlrp3− /− compared to WT cells (Fig. 4a), whereas the current flow between cells was 
not significantly different between WT and Nlrp3− /− cells (Fig. 4b). In order to confirm our results obtained 
from ECIS measurements showing diminished cellular adhesion in Nlrp3− /− cells, we performed live TIRF 
microscopy (TIRFM) using a lipophilic membrane dye. Fluorescence intensity correlates with areas of cellular 
adhesion within 200 nm distance from the glass bottom and can be quantified using a particle analysis tool. We 
observed loss of cellular adhesion upon addition of PLY in AECs, which seemed to further decrease by lack of 
NLRP3 (Fig. 4c,d). However, although we observed a moderate increase in apoptotic and/or necrotic epithelial 
cell death upon PLY treatment, cell death was not affected by NLRP3 deficiency (Fig. 4e–g). In summary, these 
results indicate that NLRP3 improves the attachment of AECs to fibronectin-containing matrices.
Discussion
We demonstrate here that NLRP3 protects the alveolar barrier upon pneumococcal infection or PLY chal-
lenge. Previous studies showed that epithelial NLRP3 and NLRP6 inflammasomes protect the intestinal bar-
rier integrity by stimulating an IL-18-dependent cell proliferation in the reconstitution phase after DSS-induced 
injury25,26,31. We initially hypothesised that it might protect the alveolar epithelium via a similar inflammasome- 
and IL-18-dependent mechanism. However, the compromised lung barrier function in S. pneumoniae-infected 
Nlrp3− /− compared to WT animals was not associated with decreased levels of IL-1β and IL-18 at the tested time 
point. Moreover, lack of ASC, IL-18 or IL-1β did not affect the barrier function in isolated perfused and ventilated 
lungs. Finally, AEC monolayers of Casp1− /− , Il1b− /− or Il18− /− mice did not demonstrate enhanced barrier 
dysfunction upon PLY treatment. Although we cannot exclude the possibility of additional inflammasome- and/
or IL-18-dependent barrier preserving mechanisms in the lung at the healing stage, our results clearly indicate 
that NLRP3 is able to protect the alveolar epithelium in an inflammasome-, IL-18- and IL-1β -independent fash-
ion during the acute stage of injury.
There have been previous reports indicating the involvement of inflammasome components in 
cytokine-independent functions in the epithelium. NLRP3, for example, has been shown to contribute to renal 
ischemia-reperfusion injury independently of ASC, IL-1β and IL-1832. Moreover, inflammasome-independent 
NLRP3 was shown to facilitate the epithelial-mesenchymal transition of kidney epithelial cells by enhancing 
TGF-β signaling and R-Smad activation21.
In our study, measurement of the current flow under AEC monolayers as well as TIRF microscopy demon-
strated increased detachment of Nlrp3− /− AECs compared to WT cells upon PLY treatment, which was 
not associated with enhanced cell death. These results suggest that NLRP3 increases AEC attachment to 
fibronectin-containing matrices, such as the basal membrane. The mechanism of how NLRP3 affects the adher-
ence of AECs and whether this is mediated by type I or II AECs is unclear at this stage and should be elucidated 
in future studies.
Interestingly, NLR molecules might be able to regulate epithelial attachment and detachment in different ways. 
Hardt et al. recently showed that NAIP5 controls expulsion of infected intestinal epithelial cells from monolayers 
independently of IL-1β and IL-1833. Future studies should further explore how specific NLRs influence cell adhe-
sion as well as junctional molecules on epithelial cells in different organs.
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Figure 3. The protective effect of NLRP3 for the alveolar permeability is independent of inflammasomes, 
IL-1β and IL-18. (a–c). Permeability of isolated perfused and ventilated lungs from WT, Asc− /− , Il1a/b− /− and 
Il18− /− was measured by HSA ELISA. (d–f) AECs isolated from WT, Casp1/11− /− , Il1a/b− /− and Il18− /− mice 
and grown on gold electrodes were treated with 1 μ g/ml PLY and resistance was measured continuously for 2 hours. 
(g) Isolated perfused and ventilated lungs from WT and Nlrp3− /− J (Jax® mice) mice were intratracheally treated 
with PBS or PLY (0.2 μ g/lung), and lung permeability was determined 30 min after stimulation by measuring 
leakage of HSA from the perfusion system to the broncho-alveolar space. Values represent a mean of 4–12 
independent experiments and are given as mean ± SEM. Statistical significance of the resistance drop was measured 
30 min after PLY stimulation (indicated by grey dotted line). * p < 0.05, * * p < 0.01, n.s. = not significant.
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In conclusion, our study reveals a novel function of NLRP3 in lung barrier protection independently of 
inflammasomes, IL-1β and IL-18. In the future, therapeutic stimulation of NLRP3 might be useful to stabilize the 
lung barrier function during pneumonia.
Methods
Bacterial strains. S. pneumoniae serotype (ST)3 strain PN36 (NCTC7978) and ST2 strain D39 strain 
were used. Bacteria were grown in THY media at 37 °C and 5% CO2 until reaching a logarithmic growth phase. 
Pneumolysin (PLY) was produced and purified as previously described34.
Murine pneumonia model. Animal procedures were approved by local authority (LAGeSo Berlin, Charite 
Berlin) and the methods were carried out in accordance with the approved guideline. 8–10 week female mice 
were anesthetized by i.p. ketamine (1.6 mg) and xylazine (0.5 mg) and transnasally infected with 5 × 106 CFU S. 
pneumoniae PN36 or D39 for 24 h18,23,35. To estimate lung microvascular leakage, human serum albumin (HSA) 
Figure 4. NLRP3 enhances attachment of alveolar epithelial cells. Attachment (a) as well as junctional 
stability (b) upon PLY treatment of WT and Nlrp3− /− AECs was determined by measuring the alpha (α ) and 
Rb parameters using ECIS. Values represent a mean of ten independent experiments performed in duplicates. 
(c,d) AECs were stained with the membrane dye DiO and subsequently subjected to TIRFM life imaging. 
Pictures were taken at 30 min after adding medium without (−) and 45 min after changing media containing PLY 
(1 μ g/ml). (c) Representative DiO-TIRF and DIC images are shown. (d) Particle analysis was performed from 
four fields from two independent experiments and values were normalized to cell numbers and average control 
values. (e,f,g) Cell death of WT and Nlrp3− /− AEC treated for 30 min with PLY (1 μ g/ml) was measured by LDH 
release (e), Sytox staining (f) and AnnexinV staining (g). (e,f,g) Data represent the mean of three independent 
experiments. All data are given as mean ± SEM * p < 0.05, * * p < 0.01, * * * p < 0.001, * * * * p < 0.0001, n.s. = not 
significant.
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was infused intravenously 1 h before broncheo-alveolar lavage (BAL). HSA concentration in BAL fluid (BALF) 
and serum was measured by ELISA, and the HSA BALF/serum ratio was calculated
Determination of bacterial load and cell recruitment. Bacterial loads were determined in BALF and 
blood. Serial dilutions of samples were plated on blood agar and colony forming units (CFU) were counted. To 
test for cell recruitment, cells were enriched by spinning the BALF (400 g 10 min RT), incubated with block-
ing antibody (anti-CD16/32, Biolegend) and stained using CD11c-FITC (N418, Biolegend), SiglecF-PE (E50-
2440, BD bioscience), Ly6C-PerCp (HK1.4, Biolegend), F4/80-APC (BM8, Biolegend), CD45-Alexa700 (30-F11, 
Biolegend), Ly6G-BV421 (1A8, Biolegend) and CD11b-BV510 (M1/70, Biolegend). 
ELISA. Concentrations of murine IL-1β in BALF or in cell-free supernatants were quantified by commercially 
available sandwich ELISA kit (eBioscience, Frankfurt, Germany; R&D, Minneapolis, USA). Murine IL-18 was 
measured by specific ELISA (R&D Systems, UK, and MBL, Japan).
Isolated perfused and ventilated mouse lung (IPML). Lungs of wild-type (WT), Nlrp3− /− 36, Nlrp3− /− J 
(The Jackson Laboratory, Stock No: 021302) and Asc− /− 37 mice were prepared according to the experimental 
setup described previously23. In short, mice were anesthetized and placed in a 37 °C chamber. After laparot-
omy, sternotomy, and cannulation (left atrium, pulmonary artery), lungs were perfused with electrolyte solution 
(Serag-Wiessner, Germany) supplemented with sodium bicarbonate. The chamber was closed and lungs were 
ventilated and perfused for 20 min to establish baseline conditions. 10 min prior to PLY application, HSA was 
added to the perfusate. For PLY-stimulation, the chamber was opened and lungs were treated intratracheally with 
0,2 μ g toxin/lung. At 30 min perfusion/ventilation with closed chamber albumin concentration was measured in 
the BAL fluid after the experiment using an ELISA (Bethyl, US).
Isolation of primary cells. Primary cells were isolated from WT, Nlrp3−/−, casp1−/−, Il1a/b−/− and Il18−/− 
animals on a C57Bl/6J background. For isolation of alveolar epithelial cells (AECs), lung homogenates were pre-
pared and leukocytes and endothelial cells were depleted from the cell suspension by incubation with biotinylated 
rat anti-mouse CD45, CD16/32 and CD31 (BD Pharmingen, Heidelberg, Germany) followed by magnetic sepa-
ration. AECs were cultured for 4 days in DMEM medium supplemented with 25 mM HEPES, 1% Glutamine, 1% 
Penicilin/Streptomycin and 10% FCS. Murine lung endothelial cells (MLECs) were isolated from lung homoge-
nates by positive magnetic selection using biotinylated rat anti-mouse CD144 (BD Pharmingen). MLECs were 
grown in Endothelial Cell Growth Medium MV2 (Promocell) supplemented with 1% Penicilin/Streptomycin 
and 15% FCS. Isolated cells were washed and stained with CD326-BV421 (G8.8, Biolegend) for epithelial cells 
and CD144-Alex647 (BV13, Biolegend) for endothelial cells, respectively. For cell culture, plates were coated with 
fibronectin (Sigma-Aldrich, USA). Alveolar macrophages (AMΦ ) were obtained by BALF from mouse lungs. For 
co-culture experiments, AMΦ were isolated 1 day before the experiment and were added to AEC cultures in a 
ratio of 1:20.
Electric Cell Substrate Impedance Sensing (ECIS). ECIS measurements of epithelial and endothelial 
cell monolayers were performed as described previously for endothelial cells23. AECs and microvascular endothe-
lial cells (MLECs) were seeded on Fibronectin-coated 8W10E+ electrodes (Applied Biophysics) and grown to 
confluence. The cells were treated with 1 μ g/ml PLY (for AECs) and 0.5 μ g/ml PLY (for MLECs). Monolayer 
resistance was measured at 37 °C and 5% CO2 using a 1600R ECIS system (Applied Biophysics) at 4000 Hz. ECIS 
software (v1.2.50.0 PC, Applied Biophysics) was used to calculate the alpha (α ) and the Rb parameter. Resistance 
data at 30 min after PLY treatment were statistically analyzed by Student’s t-test (two-tailed, unpaired).
Flow Cytometry. All the FACS data were acquired on FACS CantoII (Becton Dickinson, Franklin Lakes, NJ, USA). 
Gating strategy was processed after exclusion of the doublets. Data were analysed using the data analysis software, 
FlowJo (Ashland, OR, USA).
Total internal reflection fluorescence microscopy (TIRFM). For TIRFM, AECs were grown on 
fibronectin-coated μ -slide 8 well glass bottom slides (Ibidi) for 4 days and stained with 5 μ l/ml Vybrant DiO cell 
labeling solution (Thermofisher) for 10 min at 37 °C. Life imaging was performed in the imaging facility of the 
Molecular Biophysics group, HU Berlin on a Confocal Laser Scanning Microscope (Olympus FV-1000MPE) 
equipped with a TIRFM upgrade at 37 °C and 5% CO2 using a 63x oil objective and a cooled CCD camera. Images 
were taken at indicated time points and analysed using FijI. Particle analysis was performed from binary images 
after thresholding (method Isodata). Total intensity of attachment from all detected particles was measured.
Cell death analysis. Cell death of PLY-treated AECs (30 min, 1 μ g/ml) was determined by the spontane-
ous release of lactate dehydrogenase (LDH) using the CytoTox 96 Assay (Promega). LDH assay was performed 
according to the manufacturer’s instructions. Moreover, to confirm the cell death data, SYTOX Orange Nucleic 
Acid stain (Molecular probes, Thermofisher Scientific) was used. AECs were pre-incubated SYTOX Orange 
for 10 min (dilution 1:10 000) and the increase in fluorescence intensity upon PLY treatment was measured 
with FilterMax F3 Multi-Mode Microplate Reader (Molecular Devices, USA). Additionally, AnnexinV-APC 
(Biolegend) was used following the instruction of manufacturer. The data were standardized by subtracting the 
percentage of PLY-treated AnnexinV+ cells from the percentage of AnnexinV+ cells in non-treated samples.
Data analysis. Data are expressed as mean ± SEM. For comparison of two groups, Mann-Whitney U Test was 
used when the data values were not normally distributed. Student t-test was used for the particle analysis of TIRFM 
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data. Data analysis was performed using the Prism software (GraphPad Software, La Jolla, CA). For all statistical 
analysis, p values < 0.05 were considered significant with * p < 0.05,* * p < 0.01, * * * p < 0.001, * * * * p < 0.0001.
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